A number of other research analysts have also weighed in on the company. Credit Suisse Group lowered Pharmerica Corporation from an outperform rating to a neutral rating and increased their price objective for the company from $29.00 to $29.25 in a report on Friday, August 4th. They noted that the move was a valuation call. UBS AG reissued a neutral rating and issued a $29.25 price objective (up from $26.00) on shares of Pharmerica Corporation in a report on Thursday, August 3rd. Barrington Research lowered Pharmerica Corporation from an outperform rating to an underperform rating in a report on Thursday, August 3rd. BidaskClub lowered Pharmerica Corporation from a hold rating to a sell rating in a report on Monday, July 31st. Finally, Zacks Investment Research lowered Pharmerica Corporation from a buy rating to a hold rating in a report on Tuesday, July 18th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. The company presently has an average rating of Hold and an average price target of $28.83.
Pharmerica Corporation (NYSE PMC) remained flat at $29.05 during midday trading on Tuesday. 497,567 shares of the company’s stock traded hands. Pharmerica Corporation has a 12-month low of $19.20 and a 12-month high of $29.10. The firm has a market cap of $904.07 million, a PE ratio of 39.36 and a beta of 0.92. The stock has a 50 day moving average price of $27.05 and a 200 day moving average price of $25.07.
Pharmerica Corporation (NYSE:PMC) last announced its quarterly earnings data on Wednesday, August 2nd. The company reported $0.47 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.47. The business had revenue of $592 million for the quarter, compared to analyst estimates of $592.96 million. Pharmerica Corporation had a return on equity of 10.94% and a net margin of 1.05%. The company’s revenue was up 13.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.47 earnings per share. On average, analysts expect that Pharmerica Corporation will post $1.92 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Pharmerica Corporation (NYSE:PMC) Stock Rating Lowered by KeyCorp” was originally published by Rincon Hill News and is the property of of Rincon Hill News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://rinconhillneighbors.org/2017/08/19/keycorp-lowers-pharmerica-corporation-nysepmc-to-overweight-updated.html.
Several hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its stake in shares of Pharmerica Corporation by 51,604.4% in the first quarter. BlackRock Inc. now owns 3,975,551 shares of the company’s stock worth $93,027,000 after buying an additional 3,967,862 shares during the last quarter. Sessa Capital IM L.P. bought a new stake in shares of Pharmerica Corporation during the first quarter worth approximately $11,968,000. Royce & Associates LP increased its stake in shares of Pharmerica Corporation by 966.5% in the second quarter. Royce & Associates LP now owns 426,600 shares of the company’s stock worth $11,198,000 after buying an additional 386,600 shares during the last quarter. Victory Capital Management Inc. increased its stake in shares of Pharmerica Corporation by 40.1% in the second quarter. Victory Capital Management Inc. now owns 1,294,142 shares of the company’s stock worth $33,971,000 after buying an additional 370,266 shares during the last quarter. Finally, Nuveen Asset Management LLC increased its stake in shares of Pharmerica Corporation by 61.3% in the first quarter. Nuveen Asset Management LLC now owns 863,975 shares of the company’s stock worth $20,217,000 after buying an additional 328,257 shares during the last quarter. Hedge funds and other institutional investors own 94.25% of the company’s stock.
About Pharmerica Corporation
Receive News & Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related companies with our FREE daily email newsletter.